Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Atossa Therapeutics Unveils Financial Progress and Strategic Insights for 2025 Atossa Therapeutics provides an overview of its financial results for 2025, focuses on innovative oncology therapies and strategic advancements.

Atossa Therapeutics Unveils Financial Progress and Strategic Insights for 2025 #United_States #Seattle #Clinical_Trials #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Atossa Therapeutics Expands its Leadership Team to Drive Clinical Development Forward Atossa Therapeutics welcome two new executives with extensive experience in biopharma, enhancing their clinical leadership to advance innovative therapies.

Atossa Therapeutics Expands its Leadership Team to Drive Clinical Development Forward #United_States #Seattle #Atossa_Therapeutics #Kathy_Theall #Adebola_Giwa

Thiard News@F4F

@newsen.bsky.social

1 month ago

Atossa Therapeutics Updates on Promising (Z)-Endoxifen Research at MDA Conference Atossa Therapeutics shared exciting updates on (Z)-endoxifen research at the MDA Clinical & Scientific Conference, showing promise for DMD treatments.

Atossa Therapeutics Updates on Promising (Z)-Endoxifen Research at MDA Conference #USA #Orlando,_FL #Duchenne_Muscular_Dystrophy #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

2 months ago

Atossa Therapeutics Reflects on 2025 Progress with Ambitious Goals for 2026 Atossa Therapeutics outlines major achievements from 2025 and sets strategic goals for 2026, focusing on cancer therapies and rare diseases.

Atossa Therapeutics Reflects on 2025 Progress with Ambitious Goals for 2026 #USA #Seattle #oncology #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

2 months ago

Atossa Therapeutics Upholds Market Presence for (Z)-Endoxifen Amid PRV Program Renewal Atossa Therapeutics reaffirms its market position for (Z)-endoxifen in Duchenne Muscular Dystrophy as the PRV program is reauthorized. This advancement signifies hope for better treatment options.

Atossa Therapeutics Upholds Market Presence for (Z)-Endoxifen Amid PRV Program Renewal #USA #Seattle #DMD #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

2 months ago

Atossa Therapeutics CEO Steven Quay Joins Top 50 Healthcare Tech Leaders of 2025 Dr. Steven Quay, at Atossa Therapeutics, has been honored as one of the top healthcare technology CEOs of 2025, recognized for his leadership and innovations.

Atossa Therapeutics CEO Steven Quay Joins Top 50 Healthcare Tech Leaders of 2025 #United_States #Seattle #healthcare_technology #Atossa_Therapeutics #Steven_Quay

Thiard News@F4F

@newsen.bsky.social

2 months ago

Atossa Therapeutics Achieves FDA Orphan Drug Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy Atossa Therapeutics has received Orphan Drug Designation from the FDA for its drug (Z)-Endoxifen, aimed at treating Duchenne muscular dystrophy, marking a significant advancement in their development efforts.

Atossa Therapeutics Achieves FDA Orphan Drug Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy #United_States #Seattle #Duchenne_Muscular_Dystrophy #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

3 months ago

Atossa Therapeutics Receives FDA Clearance to Proceed with Study on (Z)-Endoxifen for Metastatic Breast Cancer Atossa Therapeutics announced the FDA has issued a 'Study May Proceed' letter for its investigational drug (Z)-endoxifen, targeting metastatic breast cancer.

Atossa Therapeutics Receives FDA Clearance to Proceed with Study on (Z)-Endoxifen for Metastatic Breast Cancer #United_States #Seattle #Breast_Cancer #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

3 months ago

Atossa Therapeutics Honored with Excellence Award for Revolutionary Endocrine Therapy Research in 2025 Atossa Therapeutics has been awarded in 2025 for its groundbreaking work in endocrine therapy, particularly highlighting the potential of (Z)-Endoxifen across various health settings.

Atossa Therapeutics Honored with Excellence Award for Revolutionary Endocrine Therapy Research in 2025 #USA #Seattle #Clinical_Trials #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

4 months ago

Atossa Therapeutics Receives FDA Designation for (Z)-Endoxifen to Treat Duchenne Muscular Dystrophy Atossa Therapeutics gains a significant regulatory milestone as the FDA grants Rare Pediatric Disease designation for (Z)-Endoxifen targeting Duchenne Muscular Dystrophy, heralding new hope.

Atossa Therapeutics Receives FDA Designation for (Z)-Endoxifen to Treat Duchenne Muscular Dystrophy #USA #Seattle #Duchenne_Muscular_Dystrophy #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

4 months ago

Atossa Therapeutics Secures U.S. Patent for (Z)-Endoxifen: A Major Advancement in Breast Cancer Treatment Atossa Therapeutics has announced a new U.S. patent for (Z)-endoxifen, targeting breast cancer therapies and hormone-related conditions. This strengthens their innovative pipeline significantly.

Atossa Therapeutics Secures U.S. Patent for (Z)-Endoxifen: A Major Advancement in Breast Cancer Treatment #USA #Seattle #Breast_Cancer #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

4 months ago

Atossa Therapeutics Unveils Fast-Track FDA Strategy for (Z)-Endoxifen's Breast Cancer Treatment Atossa Therapeutics is advancing its (Z)-Endoxifen program with a clear strategy for expedited FDA approval across breast cancer indications, aiming for quicker treatments.

Atossa Therapeutics Unveils Fast-Track FDA Strategy for (Z)-Endoxifen's Breast Cancer Treatment #United_States #Seattle #FDA_Approval #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

4 months ago

Atossa Therapeutics Explores Potential of (Z)-Endoxifen for Duchenne Muscular Dystrophy Treatment Atossa Therapeutics is pursuing the use of (Z)-endoxifen for Duchenne Muscular Dystrophy, focusing on its effects and potential benefits for female carriers.

Atossa Therapeutics Explores Potential of (Z)-Endoxifen for Duchenne Muscular Dystrophy Treatment #United_States #Seattle #Duchenne_Muscular_Dystrophy #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

5 months ago

Atossa Therapeutics Reflects on Q3 2025 Financial Progress and Future Strategies Atossa Therapeutics provides insights into its Q3 2025 financial results, ongoing initiatives, and plans to enhance its pipeline, including strategies for (Z)-endoxifen.

Atossa Therapeutics Reflects on Q3 2025 Financial Progress and Future Strategies #United_States #Seattle #Breast_Cancer #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

5 months ago

Atossa Therapeutics to Showcase (Z)-Endoxifen Research at 2025 San Antonio Symposium Atossa Therapeutics is set to present four abstracts at the upcoming San Antonio Breast Cancer Symposium, showcasing vital findings on (Z)-endoxifen.

Atossa Therapeutics to Showcase (Z)-Endoxifen Research at 2025 San Antonio Symposium #USA #San_Antonio #Breast_Cancer #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

5 months ago

Atossa Therapeutics Advances Innovative Cancer Treatment Strategies at Research Conference Atossa Therapeutics highlights its progress in the RECAST™ trial for DCIS at the Early Detection Research Conference, focusing on new treatment strategies and surveillance protocols.

Atossa Therapeutics Advances Innovative Cancer Treatment Strategies at Research Conference #USA #Portland #Atossa_Therapeutics #Z-Endoxifen #RECAST_trial

Thiard News@F4F

@newsen.bsky.social

6 months ago

Atossa Therapeutics Highlights Future Growth at Maxim Growth Summit 2025 Atossa Therapeutics to showcase its innovative approaches to breast cancer treatment at the Maxim Growth Summit 2025, emphasizing growth and strategic investments.

Atossa Therapeutics Highlights Future Growth at Maxim Growth Summit 2025 #USA #New_York_City #Atossa_Therapeutics #Nasdaq_ATOS #bio-pharmaceuticals

Thiard News@F4F

@newsen.bsky.social

6 months ago

Atossa Therapeutics Elevates Mark Daniel to Chief Financial Officer for Strategic Growth Atossa Therapeutics has appointed Mark Daniel as CFO, focusing on finance, systems, and capital strategy as the company gears up for commercial operations.

Atossa Therapeutics Elevates Mark Daniel to Chief Financial Officer for Strategic Growth #United_States #Seattle #CFO #Atossa_Therapeutics #Mark_Daniel

Thiard News@F4F

@newsen.bsky.social

6 months ago

Atossa Therapeutics Strengthens Patent Protection for Z-Endoxifen with Recent Developments in Israel Atossa Therapeutics has made significant strides in its global patent strategy for Z-endoxifen, including new protections in Israel, reinforcing its clinical programs.

Atossa Therapeutics Strengthens Patent Protection for Z-Endoxifen with Recent Developments in Israel #Atossa_Therapeutics #Z-Endoxifen #Patent_Protection

Thiard News@F4F

@newsen.bsky.social

6 months ago

Atossa Therapeutics Optimizes EVANGELINE Breast Cancer Trial for 2026 Regulatory Activities Atossa Therapeutics has revised its EVANGELINE trial design to improve efficiency and focus on 2026 NDA-enabling efforts, reducing costs and expediting study outcomes.

Atossa Therapeutics Optimizes EVANGELINE Breast Cancer Trial for 2026 Regulatory Activities #United_States #Seattle #Atossa_Therapeutics #Z-Endoxifen #EVANGELINE_Study

Thiard News@F4F

@newsen.bsky.social

6 months ago

Atossa Therapeutics Appoints Janet R. Rea to Accelerate R&D for Breast Cancer Drug (Z)-Endoxifen Atossa Therapeutics announces the appointment of Janet R. Rea as Senior VP of R&D, aimed at fast-tracking (Z)-endoxifen through key regulatory pathways for breast cancer.

Atossa Therapeutics Appoints Janet R. Rea to Accelerate R&D for Breast Cancer Drug (Z)-Endoxifen #USA #Seattle #Atossa_Therapeutics #(Z)-endoxifen #Janet_R._Rea

Thiard News@F4F

@newsen.bsky.social

7 months ago

Atossa Therapeutics Unveils Ambitious Strategy for Fast-Tracking Z-Endoxifen in Breast Cancer Prevention Atossa Therapeutics has initiated a regulatory strategy to expedite the development of low-dose (Z)-endoxifen aimed at reducing breast cancer risk, engaging with the FDA strategically.

Atossa Therapeutics Unveils Ambitious Strategy for Fast-Tracking Z-Endoxifen in Breast Cancer Prevention #USA #Seattle #Breast_Cancer #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

7 months ago

Atossa Therapeutics CEO to Present Milestones at H.C. Wainwright Conference Join Atossa Therapeutics as CEO Dr. Steven Quay shares updates on clinical advances and future milestones at the H.C. Wainwright Global Investment Conference.

Atossa Therapeutics CEO to Present Milestones at H.C. Wainwright Conference #USA #New_York #Atossa_Therapeutics #Z-Endoxifen #Dr._Steven_Quay

Thiard News@F4F

@newsen.bsky.social

7 months ago

Atossa Therapeutics Partners with PSI for Crucial Trial of (Z)-Endoxifen in Advanced Breast Cancer Atossa Therapeutics has selected PSI as its CRO to oversee a pivotal study on (Z)-endoxifen for metastatic breast cancer, paving the way for future treatments.

Atossa Therapeutics Partners with PSI for Crucial Trial of (Z)-Endoxifen in Advanced Breast Cancer #USA #Seattle #Atossa_Therapeutics #PSI #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

8 months ago

Atossa Therapeutics Reports Second Quarter 2025 Financial Results and Strategic Insights Atossa Therapeutics has shared its financial results for Q2 2025, highlighting regulatory advancements and strategic plans for its drug (Z)-endoxifen aimed at breast cancer treatment.

Atossa Therapeutics Reports Second Quarter 2025 Financial Results and Strategic Insights #United_States #Seattle #Breast_Cancer #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

8 months ago

Atossa Therapeutics Closer to IND Submission for (Z)-Endoxifen in Breast Cancer Treatment Atossa Therapeutics has received positive feedback from the FDA on its IND application for (Z)-endoxifen, enhancing hope for metastatic breast cancer treatment.

Atossa Therapeutics Closer to IND Submission for (Z)-Endoxifen in Breast Cancer Treatment #USA #Seattle #FDA_Approval #Atossa_Therapeutics #(Z)-endoxifen

Thiard News@F4F

@newsen.bsky.social

8 months ago

SERM Market Anticipates Strong Growth by 2034 Due to Rising Cancer and Women's Health Needs The SERM market is set for notable expansion by 2034, driven by increased diagnoses of cancer and greater awareness around women's health issues.

SERM Market Anticipates Strong Growth by 2034 Due to Rising Cancer and Women's Health Needs #United_States #Las_Vegas #Atossa_Therapeutics #SERM_Market #Sermonix_Pharmaceuticals

Thiard News@F4F

@newsen.bsky.social

11 months ago

Atossa Therapeutics Unveils Promising Findings from I-SPY 2 Trial on Low-Dose (Z)-Endoxifen Atossa Therapeutics shares positive results from the Phase 2 I-SPY 2 trial, highlighting the effectiveness of low-dose (Z)-endoxifen in breast cancer treatment.

Atossa Therapeutics Unveils Promising Findings from I-SPY 2 Trial on Low-Dose (Z)-Endoxifen #United_States #Seattle #Breast_Cancer #Atossa_Therapeutics #Z-Endoxifen

Thiard News@F4F

@newsen.bsky.social

1 year ago

Nona Biosciences and Atossa Therapeutics Unite for Advanced Breast Cancer Antibodies Discover how Nona Biosciences and Atossa Therapeutics are set to innovate breast cancer treatment through the development of next-generation antibody therapies.

Nona Biosciences and Atossa Therapeutics Unite for Advanced Breast Cancer Antibodies #USA #Cambridge #Nona_Biosciences #Harbour_Mice #Atossa_Therapeutics